Cargando…
1638. Development of a Model to Estimate Persistence of hSBA Titers Over Time Following a Primary Series and Booster Dose of the Pentavalent Meningococcal MenABCWY Vaccine
BACKGROUND: Serogroups A/B/C/W/Y cause nearly all meningococcal disease. Therefore, comprehensive protection requires vaccination against all 5 serogroups. A pentavalent MenABCWY vaccine, composed of 2 licensed vaccines (MenB-fHbp, MenACWY-TT), is undergoing clinical development in adolescents and y...
Autores principales: | Cai, Bing, Peyrani, Paula, Beeslaar, Johannes, Maguire, Jason, Maansson, Roger, Palmer, Paul |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677189/ http://dx.doi.org/10.1093/ofid/ofad500.1472 |
Ejemplares similares
-
1146. Cost-effectiveness of the Pentavalent Meningococcal Vaccine (MenABCWY): A steady-state cohort modelling approach
por: Schley, Katharina, et al.
Publicado: (2023) -
6. Pentavalent Meningococcal (MenABCWY) Vaccine is Safe and Well Tolerated With Immunogenicity Noninferior to Coadministered MenB-FHbp and MenACWY-CRM in a Phase 2 Study of Healthy Adolescents and Young Adults
por: Peterson, James, et al.
Publicado: (2020) -
Four-year antibody persistence and response to a booster dose of a pentavalent MenABCWY vaccine administered to healthy adolescents and young adults
por: Sáez-Llorens, Xavier, et al.
Publicado: (2018) -
1084 Persistence of Meningococcal Antibodies and Response to a Booster Dose after a Two-dose Vaccination Series with Investigational MenABCWY Vaccine Formulations in Adolescents
por: Saez-Llorens, Xavier, et al.
Publicado: (2014) -
Endogenous complement human serum bactericidal assay (enc-hSBA) for vaccine effectiveness assessments against meningococcal serogroup B
por: Kleinschmidt, Annett, et al.
Publicado: (2021)